Urapidil

CARDIOVASCULAR SYSTEM

Key facts

Urapidil is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1981. DrugCentral lists 4 molecular targets, including HTR1A, ADRA1A and ADRA1D. Recorded indications include Hypertensive emergency.

• Molecular targets: HTR1A, ADRA1A, ADRA1D and ADRA1B (4 listed in DrugCentral).
• Indications: Hypertensive emergency.
• ATC code: C02CA06 (Alpha-adrenoreceptor antagonists).
• Molecular formula: C20H29N5O3; molecular weight 387.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive emergency

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 9.46
Alpha-1A adrenergic receptor	ADRA1A	antagonist	Ki 8.85
Alpha-1D adrenergic receptor	ADRA1D	antagonist	Ki 7.90
Alpha-1B adrenergic receptor	ADRA1B	antagonist	Ki 7.10

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1981-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
C02CA06	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING › Alpha-adrenoreceptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Acute kidney injury	551.3
Hyperkalaemia	280.1
Hyponatraemia	207.3
Rash maculo-papular	160.1
Eosinophilia	138.6
Hepatic cytolysis	134.6
Toxic epidermal necrolysis	130.3
Bradycardia	120.9
Product prescribing error	111.0
Hypotension	108.6
Fall	105.4
Hypoglycaemia	102.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Urapidil is on its molecule page.

• Molecular formula: C₂₀H₂₉N₅O₃
• Molecular weight: 387.48 g/mol
• CAS number: 34661-75-1
• InChIKey: ICMGLRUYEQNHPF-UHFFFAOYSA-N
• PubChem CID: 5639

COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Urapidil used for?

DrugCentral lists the following indications for Urapidil: Hypertensive emergency.

How does Urapidil work?

Its molecular targets in DrugCentral include HTR1A, ADRA1A (antagonist), ADRA1D (antagonist) and ADRA1B (antagonist).

When was Urapidil first approved?

Urapidil was first approved by the YEAR INTRODUCED in 1981.

What is the chemical formula of Urapidil?

Urapidil has the molecular formula C20H29N5O3 and a molecular weight of 387.48 g/mol.

Sources

• DrugCentral drug card 2796 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1256716 — compound record and bioactivity
• PubChem CID 5639 — chemical identifiers
• DrugBank DB12661 — drug record
• FDA UNII A78GF17HJS — substance identity
• UniProt P08908 (HTR1A) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35368 (ADRA1B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.